RxDoctor Payments Data

Amelia Kiser, MD

Family Medicine · Glasgow, KYNPI 1982605465

Payments from drug & device makers

$356in general payments, 2019–2025

Across 13 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Polymedics Innovations Inc.$177
  • Sunovion Pharmaceuticals Inc.$30
  • Urgo Medical North America, LLC$26
  • Cipher Pharmaceuticals US LLC$25
  • Alkermes, Inc.$23
  • Medline Industries LP$19
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Polymedics Innovations Inc.3$177
Sunovion Pharmaceuticals Inc.2$30
Urgo Medical North America, LLC1$26
Cipher Pharmaceuticals US LLC1$25
Alkermes, Inc.1$23
Medline Industries LP1$19
Melinta Therapeutics, LLC1$16
Acadia Pharmaceuticals Inc1$15
Merck1$14
AbbVie1$11

How this compares

$356 in reported general payments places this provider in the 35th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$49,447
Medicare patients
321
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,401$394,893
XareltoRivaroxaban267$72,414
Orencia ClickjectAbatacept43$64,677
LinzessLinaclotide78$44,897
JanuviaSitagliptin Phosphate140$39,785
JardianceEmpagliflozin127$38,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$35,310
TrulicityDulaglutide94$30,093
Potassium Chloride866$27,619
Invega SustennaPaliperidone Palmitate11$26,906
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog241$26,887
Midodrine Hcl129$26,475
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$22,606
MyrbetriqMirabegron120$22,217
Divalproex Sodium326$21,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$11$44,89778 claims
MerckJanuvia$14$39,785140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →